The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation

Monday, January 02, 2012

Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation17:19 EST Monday, January 02, 2012TARRYTOWN, N.Y., Jan. 2, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. Eastern Time to provide an update on the status of the ongoing patent litigation with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY).Conference Call InformationDomestic Dial-in Number: (888) 660-6127International Dial-in Number: (973) 890-8355Participant Code:  40392582An archived version of the conference call will be available for 30 days on the company's website at www.regeneron.com on the Investor Relations page.About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA? (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.  Contact Information:   Michael Aberman, M.D. Peter DworkinInvestor Relations                                                    Corporate Communications914.847.7799                                                          914.847.7640                        michael.aberman@regeneron.com                   peter.dworkin@regeneron.com SOURCE Regeneron Pharmaceuticals, Inc.